Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
Version v2-FR | Version v1-EN | |
---|---|---|
Language | French | English |
Date Updated | 2018-05-10 | 2018-05-10 |
Drug Identification Number | 00318736 | 00318736 |
Brand name | PROSTIN F2 ALPHA | PROSTIN F2 ALPHA |
Common or Proper name | PROSTIN F2A | PROSTIN F2A |
Company Name | PFIZER CANADA ULC | PFIZER CANADA ULC |
Ingredients | DINOPROST | DINOPROST |
Strength(s) | 5MG | 5MG |
Dosage form(s) | SOLUTION | SOLUTION |
Route of administration | INTRA-AMNIOTIC | INTRA-AMNIOTIC |
Packaging size | 1 x 1ml | 1 x 1ml |
ATC code | G02AD | G02AD |
ATC description | UTEROTONICS | UTEROTONICS |
Reason for discontinuation | Other (Please describe in comments) | Other (Please describe in comments) |
Anticipated discontinuation date | 2018-09-30 | 2018-09-30 |
Actual discontinuation date | ||
Remaining supply date | 2018-09-30 | 2018-09-30 |
Discontinuation status | To be discontinued | To be discontinued |
Discontinuation decision reversal | no | no |
Tier 3 Status | No | No |
Information on remaining supply | ||
Company comments | The product discontinuation is due to low market demand. | The product discontinuation is due to low market demand. |
Health Canada comments |